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Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with protection from severe malaria,
and potentially uncomplicated malaria phenotypes. It has been documented that G6PD deficiency in sub-Saharan Africa
is due to the 202A/376G G6PD A-allele, and association studies have used genotyping as a convenient technique
for epidemiological studies. However, recent studies have shown discrepancies in G6PD202/376 associations with severe
malaria. There is evidence to suggest that other G6PD deficiency alleles may be common in some regions of West Africa,
and that allelic heterogeneity could explain these discrepancies.
Methods: A cross-sectional epidemiological study of malaria susceptibility was conducted during 2006 and 2007 in
the Sahel meso-endemic malaria zone of Mali. The study included Dogon (n = 375) and Fulani (n = 337) sympatric
ethnic groups, where the latter group is characterized by lower susceptibility to Plasmodium falciparum malaria.
Fifty-three G6PD polymorphisms, including 202/376, were genotyped across the 712 samples. Evidence of association
of these G6PD polymorphisms and mild malaria was assessed in both ethnic groups using genotypic and haplotypic
statistical tests.
Results: It was confirmed that the Fulani are less susceptible to malaria, and the 202A mutation is rare in this group
(< 1% versus Dogon 7.9%). The Betica-Selma 968C/376G (~11% enzymatic activity) was more common in Fulani
(6.1% vs Dogon 0.0%). There are differences in haplotype frequencies between Dogon and Fulani, and association
analysis did not reveal strong evidence of protective G6PD genetic effects against uncomplicated malaria in both
ethnic groups and gender. However, there was some evidence of increased risk of mild malaria in Dogon with the
202A mutation, attaining borderline statistical significance in females. The rs915942 polymorphism was found to be
associated with asymptomatic malaria in Dogon females, and the rs61042368 polymorphism was associated with
clinical malaria in Fulani males.
Conclusions: The results highlight the need to consider markers in addition to G6PD202 in studies of deficiency.
Further, large genetic epidemiological studies of multi-ethnic groups in West Africa across a spectrum of malaria
severity phenotypes are required to establish who receives protection from G6PD deficiency.
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Background
Geographical, epidemiological and in vitro evidence sug-
gest the hypothesis that glucose-6-phosphate dehydro-
genase (G6PD) deficiency confers protection from malaria
disease caused by the Plasmodium falciparum parasite [1].
G6PD is a key component in the pentose phosphate
pathway used by erythrocytes to handle oxidative damage.
Following invasion of host erythrocytes, malaria parasites
digest haemoglobin to obtain nutrients for their growth.
This process releases toxic products, inducing oxidative
stress on the cell. G6PD is encoded by a 16.2 kb gene
located on the X chromosome. Approximately 160 genetic
variants causing clinical deficiency of G6PD have been
characterized, and the geographical distribution of these
alleles is closely related to populations’ history of exposure
to endemic malaria [2].
Establishing whether malaria patients are G6PD
deficient is important, because of the future need to
use 8-aminoquinolines (e.g., primaquine (PQ) and its
derivatives) for malaria elimination in sub-Saharan Africa.
PQ is active against all liver stages of Plasmodium, and
also offers activity against P. falciparum gametocytes,
thereby blocking transmission to mosquitoes. However,
PQ has low oral bioavailability and is haemotoxic, and can
cause haemolytic anaemia in G6PD-deficient individuals.
The deficiency can be quantified using enzymatic activity
assays, which may be difficult to interpret, especially for
mosaic female heterozygotes [3]. Cytochemical methods
have been suggested as an alternative [3], but genotyping
has been used as a high throughput approach in epidemio-
logical studies. G6PD A- deficiency is the commonest type
in sub-Saharan Africa. The presence of 202A/376G alleles
(with ~12% reduced enzymatic activity) has been used for
association studies to assess the degree to which female
heterozygotes and male hemizygotes are protected against
severe malaria. Associations between presence of the
G6PD202/376 polymorphism and protection against se-
vere malaria have been inconsistent across large studies,
observing protective effects in females [4], in males [5,6],
in both [7], or no protection [8,9]. The discrepancies
could be explained in part by variation in phenotype def-
inition, choice of controls (village surveys vs hospital-
based studies), age or immune status of subjects, and
study designs (case control vs cohort) [8]. The techniques
used to identify G6PD-deficient individuals are import-
ant, as demonstrated by a recent study observing uncom-
plicated malaria protection only when characterizing
deficiency using enzymatic activity from biochemical as-
says, but not genotyping of G6PD202 [10]. It has also
been recognized that allelic heterogeneity has a role in
explaining inconsistencies between phenotype and geno-
type, with evidence from studies in West Africa [5,8] for
A-, as well as in Southeast Asia and Oceania for other
deficiency types [2]. In the West African setting, the 202A
allele frequency across ethnic groups is frequently substan-
tially lower than deficiency rates, and inclusion of alterna-
tive G6PD alleles (Santamaria 542 T/376G - ~2% residual
enzymatic activity, Betica-Selma 968C/376G - ~11%
activity) [11,12] has captured an association with severe
malaria in The Gambia [8].
Establishing the region-specific repertoire of G6PD
functional variation is required for genetic epidemio-
logical studies. Here G6PD polymorphisms are char-
acterized in Dogon and Fulani ethnic groups in rural
Mali (n = 712), where malaria is meso-endemic and
transmission rates inside and outside of villages are iden-
tical [13]. The polymorphisms are then associated with a
non-severe, mild malaria phenotype. Previous studies in
West Africa have reported that the Fulani are less suscep-
tible to malaria, compared to other sympatric groups
(including Dogon [13,14]), with lower parasite densities,
lower incidence and malaria prevalence [13-16]. A previ-
ous study of G6PD in the Dogon (and Malinke) ethnic
groups in urban Mali has inferred an A-/202A frequency
of 7.5% (11.0%) and 16.6% (14.9%) in severe and uncom-
plicated malaria cases, respectively, leading to protection
against severe disease in hemizygous males but not in
heterozygous females [5]. From the postulated evolution
of G6PD deficiency, it is likely that the frequency of
malaria is lower in patients with deficiency. However, a
protective effect against uncomplicated malaria has not
been conclusively demonstrated.
Fulani have higher rates of spleen enlargement and
higher levels of humoral immune responses to a variety
of malaria parasite antigens [13-16]. Malarial antigens
are sequestered in the spleen in Fulani, leading to higher
rates of spleen enlargement compared to other groups,
including Dogon [13]. The antigens in the spleen are in
contact with (memory) B and plasma cells, leading to
higher antibody production, and lower parasite densities
and malaria susceptibility in the Fulani [13]. However, in
general, immunoglobulin (IgG) antibody responses against
P. falciparum antigens can be taken as a measure of
malaria exposure, and reduced exposure a measure of
decreased risk of phenotypes, such as parasitaemia and
uncomplicated malaria [17,18]. It has been found that
plasmodial infection can also lead to IgE elevation, and
not IgG, in children with cerebral malaria compared with
patients with uncomplicated disease [19]. There is some
evidence suggesting a connection with G6PD deficiency,
with a study in Senegal that cell-mediated immune activity
may explain the clinical protection afforded by A- defi-
ciency [20]. Here, across the sympatric Dogon and Fulani
ethnic groups (n = 712) in the same transmission setting,
IgG antibody levels against the P. falciparum vaccine can-
didate antigens apical membrane antigen 1 (AMA1), mer-
ozoite surface protein 1–19 (MSP1), merozoite surface
protein 2 (MSP2), and circumsporozoite protein (CSP),
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plus total IgE levels, were quantified. These data allowed
an assessment of potential differences in ethnic stimulation
of antibody responses, as well as any underlying G6PD
A- deficiency mechanisms or genetic effects.
Methods
The study was performed in a rural village of Manteourou
in the African Sahel, where Dogon and Fulani ethnic
groups live together in sympatry, within 0.5 km of each
other. Cultural and ethnic differences mean that there
are no inter-marriages between these two groups. The
study was initiated in 2006, and at the time the popula-
tion size was estimated from the census to be approxi-
mately 5,000 inhabitants with 50% Dogon, 45% Fulani
and 5% other ethnicities (Rimaibe, Mossi). Two cross sec-
tional surveys were performed, the first at the end of the
transmission or rainy season (October/November 2006;
n = 594) and the second during the dry season (March/
April 2007; n = 345). The study populations (n = 939) in-
cluded healthy children and adults each from different
families, belonging to both ethnic groups (Dogon 53.8%;
Fulani 46.2%). In the current study we use the subset
of the population (n = 712, 75.8%; Dogon 52.7%; Fulani
47.3%) with DNA available for genotyping. At each survey,
clinical (spleen size/enlargement, axillary temperature,
body weight) and parasitological data (malaria parasite
densities and species), and blood samples were collected
(see [14]). Clinical malaria is defined as the presence of
fever (axillary temperature of at least 37.5°C) plus the
presence of P. falciparum parasites on the thick blood
smear, in the absence of any other known illnesses. Vol-
unteers visited the health centre at least every month
during the season, or were visited by a healthcare if un-
able to attend the centre, thereby actively followed up for
malaria events. If an individual had a malaria event, then
that observation was used in the analysis. Repeated
events were not considered. Ethical clearance was ob-
tained through the Institutional Review Board of the
Malian School of Medicine Pharmacy and Dentistry at
the University of Mali. Treatment for malaria and other
illnesses detected during the course of the study was pro-
vided to the study population at no cost to participants.
Community permission was obtained according to the
procedures described by previously [21].
Individual written consent was then obtained for each
examination or blood collection from the adult or from
the child’s parent or care-givers.
All genomic DNA samples (n = 712) were whole-
genome amplified by Primer Extension Pre-amplification
before genotyping on the Sequenom IPLEX genotyping
platform (Sequenom Inc., San Diego, USA) [22], at the
Wellcome Trust Centre for Human Genetics, Oxford,
as part of an ongoing project (see [14,23] for details).
Multiplex design for the iPLEX genotyping methodology
was undertaken using the MassARRAY® Assay Design
v3.1 Software, and tested using a panel of CEPH and
YRI HapMap DNAs [23]. The iPlex genotyping assays
included 68 G6PD single nucleotide polymorphism
(SNP) positions (described at [23]), HbS (rs334) and HbC
(rs33930165), and two SNPs that allow an estimate of the
ABO blood group rs8176719, rs8176746). In particular,
the rs8176719 derived allele results in a non-functional
enzyme, and group O individuals are DD, while non-O
Individuals are either II or ID. In addition, rs8176746 is
involved in the enzyme’s substrate selection and therefore
defines either the A or B blood groups. From blood serum,
ELISA was used to detect to total IgE antibody levels
[17,18]. ELISA was also used to measure levels of IgG
Figure 1 G6PD map (X chromosome). MAF = minor allele frequency, right axis has number of SNPs.
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Table 1 Study characteristics
Dogon Fulani
(n = 375, 52.7%) (n = 337, 47.3%) P-value
N (median) % (range) N (median) % (range)
Baseline characteristics
Age in months (192) (24 – 744) (168) (24 – 900) 0.25
Age groups (years) 0.31
0-4 50 13.3 50 14.8
5-9 63 16.8 60 17.8
10-15 70 18.7 77 22.8
>15 192 51.2 150 44.5
Male 174 46.4 160 47.5 0.84
Wet Season 298 79.5 259 76.9 0.45
Genetics
Blood Group 0.003*
O 161 44.7 183 55.6
B 108 30.0 62 18.8
AB 22 6.1 15 4.6
A 69 19.2 69 21.0
HbS 0.62*
AA genotype 358 97.0 327 97.9
AS genotype 11 3.0 7 2.1
HbC < 10−4
AA genotype 339 92.4 332 99.1
AC/CC genotypes 28 7.6 3 0.9
G6PD202A 29 7.7 2 0.6 < 10−4
G6PD376G 130 35.3 109 35.8 0.80
G6PD542A 375 100 337 100 -
G6PD680G 375 100 337 100 -
G6PD968T 375 100 316 93.9 -
Clinical phenotypes
Malaria 0.01*
Clinical 61 16.3 30 8.9
Asymptomatic 77 20.5 73 21.7
No malaria 237 63.2 234 69.4
Hyperparasitaemia 55 14.7 25 7.4 0.003
Parasite positivity 105 28.5 71 21.3 0.03
Spleen enlargement 34 9.1 116 34.4 < 10−6
Immunological pheno.
AMA1 (1269) (0 – 72,770) (1684) (3 – 72,770) 0.125
MSP1 (542) (0 – 131,800) (2099) (19 – 356,900) < 10−6
MSP2 (1735) (0 – 777,500) (4396) (49 – 777,500) < 10−6
CSP (747) (75 – 779,700) (1331) (0 – 1,387,000) 0.0002
Total IgE (1432) (0 – 21,780) (1702) (171 – 28,960) 0.008
*p-value for an overall effect.
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antibodies against P. falciparum antigens: AMA1 (FVO,
source: Takafumi Tusboi, Ehime University, Japan), MSP1
(K1-Wellcome allele, source: Patrick Corran, LSHTM),
MSP2 (DD2, source: David Cavanagh, Institute of Immun-
ology and Infection Research, Edinburgh, UK), and CSP
(NANP16 peptide, source: Patrick Corran, LSHTM),
(see [18] for a description of assays and data processing).
The resulting titre values were log10 transformed to sym-
metrise them for regression analysis.
To assess inter-ethnic group differences for continu-
ous variables (e.g., age in months, immunological titres),
Mann–Whitney-Wilcoxon sum-rank tests were applied.
Similarly, Pearson’s Chi-square independence tests were
applied to categorical variables (e.g., age group, parasite
positivity). All analyses involving SNPs were stratified
by gender. Genotypic deviations from Hardy-Weinberg
equilibrium (HWE) in females were assessed using a Chi-
square statistical test. SNPs were excluded from analysis
if they had at least 15% of genotype calls missing, more
than 2% of males genotype calls were (falsely) called
heterozygous, or there was significant deviation from
HWE (p < 0.0001). On this basis, 15 SNPs were excluded
(rs766420, rs766419, rs743545, rs743548, rs28470352,
rs12393550, rs2230037, rs5986990, rs762515, rs73573488,
rs2472393, b36_153426256, rs111827785, rs2071429,
rs2515904), leaving 53 high-quality SNPs for further ana-
lysis (see Figure 1).
The SNP association analysis for the (binary) malaria
and clinical phenotypes used a logistic regression model
including age group and season as covariates. The associ-
ation analysis for continuous (log10 transformed) immuno-
logical titre phenotypes used linear regression models, and
Table 2 G6PD polymorphisms and minor allele frequencies
SNP Position Major/Minor allele Dogon Fulani Fst
(n = 375) (n = 337)
rs915941 153626649 A/C 0.542 0.352 0.051
rs915942 153626738 G/A 0.435 0.277 0.043
rs762513 153675171 A/G 0.203 0.087 0.040
rs61042368 153755336 G/A 0.152 0.069 0.019
rs12389569 153757734 G/A 0.097 0.209 0.033
b36_153413623** 153760429 G/A 0.011 0.010 0.007
rs2230036 153760953 C/T 0.147 0.068 0.018
G6PD968 153761240 T/C 0.000 0.061 0.041
rs73573478 153761564 G/A 0.155 0.074 0.017
rs2515905 153762075 G/A 0.020 0.038 0.004
rs5986875 153762392 G/A 0.009 0.022 0.008
rs1050829 (376) 153763492 A/G 0.353 0.358 0.003
rs1050828 (202) 153764217 G/A 0.079 0.006 0.034
rs762516 153764663 C/T 0.105 0.112 0.001
rs73641103** 153769889 G/A 0.003 0.000 0.001
b36_153424232** 153771038 T/C 0.004 0.001 0.001
b36_153426354 153773160 A/C 0.027 0.007 0.006
b36_153426720** 153773526 A/G 0.004 0.003 0.004
rs5986992 153776107 C/A 0.000 0.022 0.017
rs5986997** 153827549 C/T 0.003 0.000 0.002
rs4898389 153827637 G/A 0.025 0.312 0.184
rs5986877 153828269 G/C 0.041 0.303 0.154
rs7879049 153829693 A/G 0.512 0.260 0.069
rs7053878 153834100 T/A 0.040 0.064 0.007
rs60030796 153836171 A/G 0.100 0.024 0.034
The following SNPs are monomorphic across both ethnic groups: rs33950507G, b36_153411172C, b36_153412566C, b36_153412620C, b36_153412734G,
b36_153412861G, b36_153413455A, rs72554665C, b36_153413799G, b36_153414077G, b36_153414378G, b36_153414531C, b36_153414709C, b36_153414937T,
b36_153415014T, 680G, b36_153415799G, rs5030868G, rs5030872A (542A), b36_153415904C, b36_153416019C, b36_153416656G, b36_153416679A,
b36_153417405A, b36_153417417A, b36_153426313G, b36_153427408T, b36_153427466T, b36_153429686G, rs5986997C.
**SNPs with minor allele frequencies less than 1% in each group, and omitted from further analysis.
Bolded are the well known 202, 376, 542, 680 and 968 polymorphisms.
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Figure 2 Pairwise linkage disequilibrium. (Top left D’, Bottom right R-square; red = 0 - > cream = 1). (a) Dogon, (b) Fulani. White lines refer to
SNPs that are monomorphic.
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included age group and season as covariates. In all
regression models, SNP data were included by fitting a
series of genetic models (additive, dominant, recessive,
heterozygous advantage, and general), and the minimum
p-value reported. The haplotypes of females were inferred
from genotypes using an expectation-maximization algo-
rithm [24]. Differences in haplotype frequencies were
assessed using Chi-square tests. Haplotype association
testing was performed using the regression models de-
scribed above [24]. Linkage disequilibrium was estimated
using the pairwise R-square and D-prime metrics [25].
Differences in linkage disequilibrium (LD) patterns be-
tween ethnic groups were assessed using a Bayesian ap-
proach [25]. Performing multiple statistical tests leads to
inflation in the occurrence of false positives. A Bonferroni
correction would be too conservative because all SNPs
are from the same gene. A permutation approach that
accounted for the correlation between tests estimated
that a p-value cut-off of 0.008 would ensure a global
significance level of 5%. All association analyses were
performed on each ethnic group separately, and where
appropriate pooled using a meta-analytical approach. All
analyses were performed using the R statistical software,
and the haplo.stat library was used to implement haplo-
type analysis.
Results
The baseline characteristics for the Dogon (n = 375,
52.7%) and Fulani (n = 337, 47.3%) are shown in Table 1.
Data from each ethnic group were matched for age, gen-
der and season (all p-values are less than 0.05). There
were inter-ethnic differences in frequency of bloods
group O (Dogon 44.7%, Fulani 55.6%, known to be pro-
tective against malaria [9]) and B (Dogon 30.0%, Fulani
18.0%) (overall P = 0.003). There was also a higher fre-
quency of the HbC-C allele in the Dogon (3.7%) com-
pared to the Fulani (0.6%) (P < 0.001, Fst 0.014), but no
difference in the HbS–S allele (Dogon 1.5%, Fulani 1.0%,
P = 0.615, Fst 0.001). Previous work in the predomin-
antly Dogon population of urban Bandiagara has simi-
larly found the frequency of HbC-C is high (8.7%) and
that of HbS-S is low (1.6%) [26]. Lower HbC-C frequen-
cies in our study may be due to differences in study
settings and designs. As expected, in the Fulani group
there were fewer individuals with any clinical malaria
case during the season (8.9% vs Dogon 16.3%, P = 0.02),
less parasite positivity (21.3 vs Dogon 28.5, P = 0.03) and
hyperparasitaemia (7.4% vs Dogon 14.7%, P = 0.003), and
greater rates of spleen enlargement (34.4% vs Dogon
9.1%, P < 10−6). Similarly, all immunoassays showed greater
median (geometric mean) levels in the Fulani with all being
statistically significant (P < 0.008) in overall analysis, except
total AMA1 (P = 0.125). By considering the genotypic
surrogates for A- deficiency, inter-ethnic differences were
observed in the 202A (Dogon 7.7%, Fulani 0.6%, P < 10−4,
Fst 0.034) and not 376G (Dogon 35.3%, Fulani 35.8%,
P = 0.80, Fst 0.003) mutations.
Of the 53 high-quality G6PD polymorphisms, 28 were
found to be monomorphic across ethnic groups (includ-
ing 680G and rs5030872A/542A, see Tables 1 and 2,
Figure 1). Of the remaining 25 SNPs, 12 and 14 had a
minor allele frequency in excess of 5% in Dogon and
Fulani, respectively. Intra-ethnic gender allele frequencies
were similar (results not shown). There were some inter-
ethnic differences (Fst median 0.015, min. 0.01, max.
0.184), with ten SNPs (including 968 T) having Fst values
of at least the same magnitude as G6PD202 (0.034). After
removing the five SNPs (b36_153413623, rs73641103,
Table 3 Haplotype frequencies
Haplotypes**** Dogon freq. Fulani freq.
Block 1*
AGA 0.330 0.640
CAA 0.387 0.201
CAG 0.049 0.076
CGA 0.080 0.073
AGG 0.128 0.006
CGG 0.027 0.004
Block 2**
GGCTGGGAGCAC 0.484 0.550
GACTGGGGGCAC 0.094 0.148
GGCTGGGGGTAC 0.026 0.070
AGTTAGGAGCAC 0.147 0.065
GACCGGGGGCAC 0.000 0.061
GGCTGAGGGTAC 0.000 0.037
GGCTGGGGGCAC 0.152 0.034
GGCTGGAAGCAA 0.000 0.022
GGCTGAGGATAC 0.019 0.004
GGCTGGGGATAC 0.056 0.002
Block 3***
GGATA 0.448 0.416
ACATA 0.000 0.239
GGGTA 0.409 0.236
ACAAA 0.025 0.050
GGGTG 0.102 0.023
AGATA 0.000 0.023
GCAAA 0.015 0.013
376G/202A and 968C are highlighted.
*rs915941 rs915942 rs762513.
**rs61042368 rs12389569 rs2230036 hG6PD_968 rs73573478 rs2515905
rs5986875 rs1050829 rs1050828 rs762516 b36_153426720 rs5986992.
***rs4898389 rs5986877 rs7879049 rs7053878 rs60030796.
****Overall differences in haplotype frequencies between ethnic groups within
each block are statistically significant (P < 0.000001).
376G/202A and 968C are bolded.
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b36_153424232, b36_153426720, rs5986997) with minor
allele frequencies less than 1%, the remaining 20 SNPs
were used to characterize LD across the gene. Pairwise
LD was high for Fulani (D’: male median 0.978, range
0.000-1.000; female median 0.981, range 0.003-1.000) and
Dogon (D’: male median 0.977, range 0.035-1.000; female
median 0.976, range 0.000-1.000) (see Figure 2 for
combined gender results). There were LD differences
between ethnic groups across the 20 SNPs (Fulani vs
Dogon P < 0.0001). Based on physical distance, three LD
blocks were constructed (Block 1: rs915941, rs915942,
rs762513; Block 2: rs61042368, rs12389569, rs2230036,
hG6PD_968, rs73573478, rs2515905, rs5986875, rs1050829,
rs1050828, rs762516, b36_153426720, rs5986992; Block 3:
rs4898389, rs5986877, rs7879049, rs7053878, rs60030796).
Inter-ethnic differences in haplotype frequencies were
observed in each block (P < 0.00001), supporting the
observation that Fulani and Dogon have different gen-
etic backgrounds (Table 3) (see Additional file 1 for all
haplotype-based results).
SNP-wide association tests were performed for the clin-
ical (Table 4, Figure 3) and immunological phenotypes
(Table 5, Figure 4) (see Additional file 2 for all results). For
the 202A polymorphism, there were indications of an
increased risk of (any non-severe) malaria risk in Dogon
(female: OR 3.108 (95% CI 1.295 - 7.460; P = 0.008); male:
OR 1.571 (95% CI 0.387 - 6.376; P = 0.528)), but in Fulani
the mutation was very rare (< 1%).
The potential compensatory effect of the 968C muta-
tion in the Fulani was not statistically significant (male:
OR 0.736, 95% CI 0.167-3.245, P = 0.684; female: OR
0.880, 95% CI 0.271- 2.865, P = 0.831). The rs915942
SNP was associated with at least a 60% protective effect
against all clinical phenotypes in Dogon females (Table 4,
P < 0.005) but not males (P > 0.8) (e.g. any malaria: fe-
males OR 0.249, 95% CI 0.116 - 0.537, P = 0.0002; males
OR 0.964 95% CI 0.450 - 2.064, P = 0.9244). The rs915941
polymorphism was in high LD with the rs915942, but with
a negative correlation, leading to some statistically signifi-
cant susceptibility effects. Three SNPs in LD (rs61042368,
rs2230036, rs73573478) with G6PD968 were associated
with increased susceptibility to clinical or any malaria
(OR >8) in Fulani males only (females OR >1, p > 0.70)
(e.g. for rs61042368 and any malaria: males OR 8.845,
95% CI 1.474 - 53.069, P = 0.0065; females OR 1.220, 95%
CI 0.415-3.589, P = 0.7190).
Table 4 Association analysis* for the clinical phenotypes
Association analysis
Alleles Dogon Fulani
SNP, gender Ref Alt Comparison OR (95% CI) P-value OR (95% CI) P-value
Any malaria
rs915941, female C A Recessive A 3.193 (1.365, 7.468) 0.0060 0.734 (0.418, 1.289) 0.2785
rs915942, female G A Dominance A 0.278 (0.130, 0.595) 0.0002 0.163 (0.016, 1.604) 0.0763
rs2515905, female G A Additive A 9.136 (1.262, 66.163) 0.0052 0.165 (0.019,1.459) 0.0533
rs1050828, female G A Additive A 3.108 (1.295, 7.460) 0.0077 ND 0.0691
rs61042368, male G A A vs. G 0.744 (0.256, 2.159) 0.5843 8.845 (1.474, 53.069) 0.0065
rs2230036, male C T T vs. C 0.701 (0.225, 2.185) 0.5376 8.819 (1.469, 52.954) 0.0066
rs73573478, male G A A vs. G 0.692 (0.214, 2.233) 0.5347 8.488 (1.413, 50.984) 0.0077
Asymptomatic malaria
rs915942, female G A Additive A 0.379 (0.212, 0.676) 0.0005 0.544 (0.270, 1.098) 0.0803
rs2515905, female G A Additive A 10.672 (1.447, 78.724) 0.0071 0.448 (0.103, 1.947) 0.2412
Clinical malaria
rs915942, female G A Dominance A 0.151 (0.041, 0.554) 0.0030 1.924 (0.582, 6.486) 0.0587
rs61042368, male G A A vs. G 0.465 (0.122, 1.766) 0.2451 24.948 (1.951, 319.05) 0.0051
rs2230036, male C T T vs. C 0.552 (0.142, 2.151) 0.3805 21.919 (1.713, 280.40) 0.0069
rs73573478, male G A A vs. G 0.542 (0.134, 2.185) 0.3775 20.851 (1.637, 265.67) 0.0078
Parasite positivity
rs915941, female C A Recessive A 4.512 (1.755, 11.600) 0.0014 1.161 (0.507, 2.658) 0.7229
rs915942, female G A Dominance A 0.185 (0.077, 0.445) 0.0001 0.178 (0.018, 1.803) 0.0996
rs1050828, female G A Additive A 4.089 (1.626, 10.279) 0.0019 ND 0.0315
ND = not determined because of low sample size, *adjusted for age and season.
P-values less than 0.008 are bolded.
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In light of potential associations amongst SNPs, haplo-
type association tests were performed using the blocks
defined above (Additional file 1). Block 1 haplotypes
AGG (vs CAA OR = 3.751, P < 0.001) and CAG (vs CAA
OR < 0.100, P < 0.001) were associated with asymptom-
atic and any malaria in Dogon females, with weaker
similar effects in the Fulani (AGG, OR > 10, P < 0.001;
CAG OR 0.580, P = 0.387). This result reinforced the
finding that haplotypes with the rs915942 mutation are
associated with uncomplicated malaria in females. Block
2 contained the rs61042368, G6PD968, 376, and 202
polymorphisms. The haplotype containing the rs61042368
mutation had weak associations with clinical outcomes
in Fulani males, but failed to reach statistical significance
(P > 0.02). There was some evidence that the haplotype
containing 202A (GGCTGAGG[A]TAC) is associated
with greater risk of asymptomatic malaria in Dogon
(OR 7.189, P = 0.004), but this observation was not statisti-
cally significant across all clinical phenotypes, nor was sig-
nificant for the other related haplotype (GGCTGGGG[A]
TAC, P > 0.11). The haplotype containing 968C (GAC[C]
GGGGGCAC) in Fulani had non-significant protective
effects across all phenotypes, including clinical malaria
(vs GGCTGGGAGCAC OR 0.673, P = 0.514). For the
immunological titres, there were few SNP associations
(MSP1 rs60030796; MSP2 rs4898389; Total IgE rs7879049),
all in females. Haplotype analysis did not reinforce these
effects.
Figure 3 Association analyses for the clinical outcomes.
Table 5 Association analysis* for the immunological phenotypes
SNP, gender Alleles Association analysis
Dogon Fulani
Ref Alt Comparison Slope (95% CI) p-value Slope (95% CI) p-value
MSP1
rs60030796, female A G Dominance G 0.500 (0.168, 0.832) 0.0032 0.286 (−0.440, 1.011) 0.4405
MSP2
rs4898389, female G A Heterozygous 0.094 (−0.581, 0.768) 0.7855 −0.352 (−0.606, −.098) 0.0066
Total IgE
rs7879049, female A G Heterozygous −0.173 (−0.297, −.049) 0.0064 −0.044 (−0.169, 0.080) 0.2303
*Adjusted for age and season.
P-values less than 0.008 are bolded.
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Discussion
Using 20 high-quality biallelic (of 68) G6PD SNPs, in-
cluding the established G6PD202, 376, and 968 markers,
allele frequencies between the Dogon and Fulani ethnic
groups were compared, and tests of association with
mild malaria phenotypes performed. There were differ-
ences in haplotype frequencies between the ethnic
groups, and association analysis did not reveal strong
evidence of protective G6PD genetic effects against
uncomplicated malaria in both ethnic groups and gender.
However, the rs915942 polymorphism (and rs915941 in
high LD) was found to be associated with asymptomatic
malaria in Dogon females, not males. Similarly, the
rs61042368 polymorphism (and rs2230036, rs73573478 in
high LD) was associated with clinical outcomes in Fulani
males, not females. Whilst one may expect a dose effect
that is greater for males than in females, differential pro-
tective G6PD polymorphism effects between genders have
been observed in studies of severe malaria, and the mecha-
nisms are not fully understood [4-6].
The 202A allele frequencies (7.7%) in Dogon are dis-
similar to those reported for controls or uncomplicated
groups in urban Bandiagara, Mali (16.6%), but similar to
the severe malaria group (7.5%) [5]. These differences
could be due to study design (case–control vs. cross-
sectional) and setting (urban vs. rural, with no inter-ethnic
marriage in the latter). In the present study, whilst the
202A mutation is common in the Dogon, it was found to
be rare in the Fulani (~1%). These observations are broadly
consistent with a recent small study in the Malian Sahel
region of Mopti (Dogon 11.9%, Fulani 2.4%) [27]. In our
study, the Betica-Selma 968C/376G, associated with ~11%
enzymatic activity, is not present in the Dogon, it has a fre-
quency of 6.1% in Fulani. Similar frequencies of compensa-
tory 968C mutations were found in a mixed Gambian
severe malaria case–control study (severe malaria 7.8%,
controls 5.4%, overall 6.0%) [8]. In that study, the Fulani
comprised 16.1% of participants, and had 202A and 986C
mutation frequencies of 3.0 and 6.3%, respectively. A large
clinical trial study of over 2,000 individuals across Africa
(including Burkina Faso) confirmed the 202A as the most
common in Africa, and did not detect 542 T, 680 T or
968C mutations [28]. These findings have been reinforced
in a recent study in Burkina Faso (202A 6.0%-14.9%, no
542 T, 680 T or 968C mutations) [29]. However, in both
studies it is unlikely that the Fulani are represented in a
large number in either study. Preliminary data from a
community-based study in Burkina Faso indicates that
the Fulani ethnic group has a 202A mutation frequency
of ~2% [23], leaving open the possibility of alternative
G6PD alleles to explain the prevalence of ~10%. In general,
data on the frequency of 542 T, 680 T or 968C mutations
is sparse in Africa. Future studies of G6PD deficiency in
Africa employing a genetic epidemiological approach may
Figure 4 Association analyses for the immunological titres.
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consider using the SNPs characterized here or establish the
region-specific repertoire of functional variation using
sequencing, before embarking on focused genotyping. This
approach is particularly essential in studies comparing
G6PD-deficient to -normal patients, for example, when
assessing the rates of parasite clearance after treatment
with artemisinin-based combination therapy [30].
Differences in malaria phenotypes and immunological
titres between Dogon and Fulani ethnic groups have
been observed, adding to the growing evidence that the
Fulani in West Africa have reduced malaria susceptibility.
It is thought that host genetics may play a part, and the
role of polymorphism in the G6PD gene was investigated.
G6PD A- deficiency is known to associate with reduced
risk of severe malaria, and the 202A polymorphism has
been used as a genotypable surrogate. Whilst there is
strong evidence that G6PD A- deficiency is protective
against severe malaria, the effect on mild forms of disease
has not been demonstrated conclusively. The results
indicate there is no strong evidence of protection to mal-
aria from 202A or 968C mutations in either ethnic group,
across gender. This could be explained by the limitations
of the sample size, the absence of severe malaria cases in
this study, or the lack of sensitivity of genotyping com-
pared to enzymatic assays [10]. However, there was some
evidence of increased risk of mild malaria in Dogon with
the 202A mutation, but it only attained borderline statis-
tical significance in females. It is possible that this result
could be explained by the presence of a flip-flop muta-
tion [31] or allelic heterogeneity [8]. The rs915942
polymorphism (and others in LD) was found to be as-
sociated with asymptomatic malaria in Dogon females.
The rs61042368 polymorphism (and others in LD) was
associated with clinical outcomes in Fulani males, but
failed to reach statistical significance in the haplotype
analysis. However, the rs61042368 is in high LD with
G6PD968, potentially suggesting a similar protective
mechanism in mild malaria as seen in severe disease
[8,32]. There are no published strong associations
between these SNPs and other disease, potentially
because in genome-wide studies, polymorphisms in the
X-chromosome tend to be somewhat overlooked com-
pared to nuclear polymorphisms. There is sparse data
concerning the effect of G6PD polymorphisms on im-
munological outcomes, with some evidence suggesting
that cell-mediated immune activity may explain the clin-
ical protection afforded by A- deficiency [20]. Although
there were no associations between 202A, 986C and titre
data, three potentially new SNP associations (MSP1 -
rs60030796, MSP2 - rs4898389, total IgE - rs7879049) in
females were identified. The potential confounding ef-
fects of chronic infections on titre values could not be
investigated, but like all associations, there is a need for
confirmation in follow-up studies.
Conclusion
Observed genetic differences in the G6PD gene between
Fulani and Dogon ethnic groups reinforce the need to
consider markers in addition to G6PD202 in studies of
deficiency. The SNPs considered in this study provide a
starting point for large-scale genetic epidemiological
studies of deficiency across Africa. These studies should
involve a broad range of ethnic groups, including Fulani,
as well as both uncomplicated and severe malaria cases,
so that it is possible to establish who receives protection
from G6PD deficiency.
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